FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma - Sahin, U; Türeci, Ö; Manikhas, G (Ann Oncol, 2021)
et al.